A Phase 3 interventional study of YouGrabber training device from YouRehab Ltd. and Therapy (PT, OT) in Cerebrovascular Accident, Hemorrhagic Stroke and Stroke, sponsored by Reha Rheinfelden. Completed at 2 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-04-07.
Sponsored by Reha Rheinfelden · Phase 3, Interventional, and Treatment
Among 12 studies in Hemorrhagic Stroke with a site in Switzerland — 3 open to participants now, 4 under way, none of them phase 3. Hemorrhagic Stroke · Switzerland.
Among the 12 studies in Hemorrhagic Stroke with a site in Switzerland, this one is the only one that started in 2013, is one of 2 in phase 3, and was the 2nd registered.
233 studies on the registry are indexed under Hemorrhagic Stroke; 93 are open to participants now.
Browse Hemorrhagic Stroke studies →3 of the 12 studies in Hemorrhagic Stroke with a site in Switzerland are open now. Recruiting first, the newest first:
Prof. Dr. Jan Liman · Sites in Switzerland, Germany
Ages 18+
University Hospital, Basel, Switzerland · Sites in Switzerland, United States, Argentina and 6 more countries
Ages 18+ · Women only
University Hospital, Basel, Switzerland · Sites in Switzerland
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 62 Hemorrhagic Stroke studies recruiting now, 36 (58%) set no upper age limit and 7 (11%) stop at 75 or younger; 5 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 54 is close to the median of 58 across 156 interventional studies indexed under Hemorrhagic Stroke.
Median enrollment 669 across the 8 interventional studies, 635 across the 4 observational. Of the 7 that completed or were terminated, 3 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 12 have an industry lead sponsor. The 8 most frequent:
Reha Rheinfelden is the lead sponsor of 5 studies on the registry; none are open to participants now.
Reha Rheinfelden has 1 study filed under Hemorrhagic Stroke — fewer than ten, so there is no comparison to draw.
1 of the studies in Hemorrhagic Stroke with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05504941University Hospital, Basel, SwitzerlandDetection of an Endovascular Treatment Target in Patients With an Acute, Spontaneous Intracerebral Hemorrhage | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Hemorrhagic Stroke with a site in Switzerland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The patient study is a phase III trial designed as a single-blinded, randomised, controlled multi-centre trial with repeated measurement events (ME). Patients will be evaluated by a blinded assessor on five occasions: twice within two weeks at baseline before intervention start (BL, T0), once after eight treatment sessions (T1), once after the intervention (T2), and once after a two month follow-up period (FU). Figure 1 illustrates the study overview.
The study focuses on the evaluation of the YouGrabber efficacy compared to conventional therapy in an outpatient setting.
Research question: Do patients after stroke in the YouGrabber training group show higher postintervention performance in the Box and Block Test (BBT) compared to patients in the conventional therapy group? Hypothesis: H0: The investigators hypothesise that there will be no group differences after 16 training sessions or after the two month follow-up period.
H1: The investigators hypothesise that there will be a group difference after the 16 training sessions and after the two month follow-up period.
Aim: The aim of the project is to design and implement a single-blinded, randomised controlled multi-centre trial comparing YouGrabber training and conventional therapy in patients after stroke.
Patients will be randomly allocated to either the experimental group (EG) or the control group (CG) after the second ME (T0). Group allocation will be based on a computer-generated randomisation list (one for each centre, (MATLAB, 2007b, Mathworks Inc., USA) created by a researcher not involved into the study. Randomisation lists and corresponding token will be stored in the clinics' pharmacy. Patients will draw a token before the first therapy session. The token will be marked and stored until study finalisation in the pharmacy.
Group allocation will remain concealed for the independent assessor until study finalisation. Patients and treating therapists will be reminded not to talk about patient's group allocation with other therapists or participants.
Patients in both study groups (EG, CG) will receive the same amount of 16 sessions lasting for 45 minutes each. During each therapy appointment patients can decide to stop the training at any time.
Patients allocated to EG will have the opportunity to participate in two semi-structured interviews to evaluate their expectations and experiences with the virtual reality therapy with YouGrabber.
Treating therapists will have the opportunity to participate in one focus group meeting to evaluate their experiences with the virtual reality training, its advantages and disadvantages. Interview and focus group participation will be voluntary.
233 studies on the registry are indexed under Hemorrhagic Stroke; 93 are open to participants now.
This study's enrollment of 54 is close to the median of 58 across 156 interventional studies indexed under Hemorrhagic Stroke.
Browse Hemorrhagic Stroke studies →Reha Rheinfelden is the lead sponsor of 5 studies on the registry; none are open to participants now.
Compared within Hemorrhagic Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in the experimental group (EG) will receive 16 training sessions lasting for 45 minutes each.
Device: YouGrabber training device from YouRehab Ltd.
Patients in the control group (CG) will receive 16 therapy sessions (physiotherapy or occupational therapy) lasting for 45 minutes each.
Other: Therapy (PT, OT)
Patients in the experimental group (EG) will receive 16 training sessions lasting for 45 minutes each. The treatment focus is the upper extremity, in particular finder and hand function, movement coordination, and speed.
Patients in the control group (CG) will receive 16 therapy sessions physiotherapy or occupational therapy) lasting for 45 minutes each. The therapy focuses on upper limb movements, in particular finger and hand movements. Furthermore, movement coordination and speed shall be trained.
Box and Block Test (BBT)
Patients will be evaluated by a blinded assessor on five occasions: twice within two weeks at baseline before intervention start (BL, T0), once after eight treatment sessions (T1), once after the intervention (T2), and once after a two month follow-up period (FU).
Time frame: 15 months
Chedoke-McMaster Stroke Assessment (CMSA)
Patients will be evaluated by a blinded assessor on five occasions: twice within two weeks at baseline before intervention start (BL, T0), once after eight treatment sessions (T1), once after the intervention (T2), and once after a two month follow-up period (FU).
Time frame: 15 months
Chedoke Arm and Hand Activity Inventory (CAHAI)
Patients will be evaluated by a blinded assessor on five occasions: twice within two weeks at baseline before intervention start (BL, T0), once after eight treatment sessions (T1), once after the intervention (T2), and once after a two month follow-up period (FU).
Time frame: 15 months
Stroke Impact Scale (SIS)
Patients will be evaluated by a blinded assessor on five occasions: twice within two weeks at baseline before intervention start (BL, T0), once after eight treatment sessions (T1), once after the intervention (T2), and once after a two month follow-up period (FU).
Time frame: 15 months
active range of motion (ROM)
Patients will be evaluated by a blinded assessor on five occasions: twice within two weeks at baseline before intervention start (BL, T0), once after eight treatment sessions (T1), once after the intervention (T2), and once after a two month follow-up period (FU).
Time frame: 15 months
Extended Barthel Index (EBI)
Time frame: 15 months
Mini Mental State Examination (MMSE)
Time frame: 15 months
Edinburgh Handedness Inventory (EHI)
Time frame: 15 months
The record gives a start of Jan 2013, a primary completion of Apr 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Reha Rheinfelden